Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | PARL | Q9H300 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293776 | 0.94 | ALDH1A1 (0.51) | CYP2C9CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6809419 | 0.85 | MAPK1 (0.47) | CYP2C9CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL27519797 | 0.81 | PKM (0.58) | CYP2C19ALDH1A1LMNAACHEPOLB | |
| SCHEMBL6809453 | 0.77 | TDP1 (0.50) | ALDH1A1LMNAPOLBGAAPKM | |
| SCHEMBL3830427 | 0.76 | CYP2C9 (0.54) | CYP2C9CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL3317094 | 0.76 | PKM (0.57) | CYP2C19ALDH1A1LMNAACHEPOLB | |
| SCHEMBL5915288 | 0.76 | L3MBTL1 (0.54) | CYP3A4ALDH1A1LMNAACHEPOLB | |
| SCHEMBL6809391 | 0.75 | ALDH1A1 (0.64) | ALDH1A1LMNAL3MBTL1TSHR | |
| SCHEMBL10742021 | 0.74 | CYP2C9 (0.48) | CYP2C9CYP3A4CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL27758823 | 0.74 | MBTD1 (0.55) | CYP2C9CYP3A4CYP2C19ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | LASSOIE MARIE-AGNES | 2010-04-29 | — | — | US | claimed |
| US-7638630-B2 | Very Late Antigen-4 dependent inflammatory disease; asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders, autoimmune disorders, or atherosclerosis, inflammatory skin disorder; methyl 3-[2-(2,6-dichlorophenyl)-6-quinolinyl]-2-hydroxy-2-propenoate | UCB PHARMA S.A. (BE) | 2009-12-29 | — | — | US | claimed |
| CN-101200450-A | 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors | UCB PHARMA SA (BE) | 2008-06-18 | — | — | CN | claimed |
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | UCB, S.A. (BE) | 2008-03-13 | — | — | US | claimed |
| EP-1501801-B1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES | UCB PHARMA SA (BE) | 2008-01-23 | — | — | EP | claimed |
| EP-1870402-A1 | 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors | UCB Pharma, S.A. (BE) | 2007-12-26 | — | — | EP | claimed |
| CN-1649842-A | 2, 6-quinolyl and 2, 6-naphthyl derivatives, processes for their preparation and their use as VLA-4 inhibitors | UCB SA (BE) | 2005-08-03 | — | — | CN | claimed |
| EP-1501801-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | UCB, S.A. (BE) | 2005-02-02 | — | — | EP | claimed |
| US-20040132809-A1 | Cell adhesion inhibitors | BIOGEN, INC. | 2004-07-08 | — | — | US | claimed |
| WO-2003093237-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | UCB, S.A. (BE) | 2003-11-13 | — | — | WO | claimed |
| US-6630503-B1 | Non-peptidic sulfonamide compounds that specifically inhibit the binding of ligands to VLA-4 for inhibition, prevention and suppression of VLA-4-mediated cell adhesion and pathologies such as inflammation and immune reactions | BIOGEN, INC. | 2003-10-07 | — | — | US | claimed |
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | LASSOIE MARIE-AGNES | 2010-04-29 | — | — | US | disclosed |
| US-7638630-B2 | Very Late Antigen-4 dependent inflammatory disease; asthma, allergic rhinitis, sinusitis, conjunctivitis, food allergy, inflammatory skin disorders, autoimmune disorders, or atherosclerosis, inflammatory skin disorder; methyl 3-[2-(2,6-dichlorophenyl)-6-quinolinyl]-2-hydroxy-2-propenoate | UCB PHARMA S.A. (BE) | 2009-12-29 | — | — | US | disclosed |
| CN-101200450-A | 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as vla-4 inhibitors | UCB PHARMA SA (BE) | 2008-06-18 | — | — | CN | disclosed |
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | UCB, S.A. (BE) | 2008-03-13 | — | — | US | disclosed |
| EP-1501801-B1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES | UCB PHARMA SA (BE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1870402-A1 | 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors | UCB Pharma, S.A. (BE) | 2007-12-26 | — | — | EP | disclosed |
| CN-1649842-A | 2, 6-quinolyl and 2, 6-naphthyl derivatives, processes for their preparation and their use as VLA-4 inhibitors | UCB SA (BE) | 2005-08-03 | — | — | CN | disclosed |
| EP-1501801-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | UCB, S.A. (BE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093237-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | UCB, S.A. (BE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | VCAM1, ICAM1, EPCAM | CYP2C9 4467/4885CYP3A4 3580/4885CYP2D6 4356/4885 |
| US-20080064720-A1 | 2,6-Quinolinyl And 2,6-Naphthyl Derivatives, Processes For Preparing Them And Their Uses As Vla-4 Inhibitors | VCAM1, HRH4, LTA4H | CYP2C9 1069/4885CYP3A4 134/4885CYP2D6 243/4885 |
| US-20100105681-A1 | 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS | SCN4A, NECTIN4, VPS4B | CYP2C9 673/4885CYP3A4 23/4885CYP2D6 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.